Skip to main content
[Preprint]. 2023 Oct 17:2023.10.13.562280. [Version 1] doi: 10.1101/2023.10.13.562280

Figure 5: Myeloid-support exhibits immuno-dampened profile in huNOG-EXL 22Rv1 xenograft tumors.

Figure 5:

A, Gating strategy used to determine presence of human CD45+ cells in the NOG-EXL model. B, Representitave data showing the abundance of various immune cell populations; human leukocytes, CD19+ cells, CD3+ cells and double negative cells, MDSC and activated myeloid cells and helper t-cells (CD4+) and cytotoxic t-cells (CD8+) (top to bottom). C, Quantitated data comparing human CD45, CD3, CD4, and CD11b populations in tumors isolated from testosterone implanted vehicle, intact vehicle, castrated vehicle, and castrated enzalutamide treated mice. D, Gating strategy for determining the activation state of MDSCs (CD3-CD19- CD11b+ CD14-). E, Representative data showing the activation state of the MDSC cells harvested from tumors under different treatment categories through the presence of the surface markers: CD25, CD44, CD69 and PD-1. F, Quantitated data showing the activation state of the MDSCs throughout the different treatments.